Eurobio Scientific (ALERS.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ALERS.PA · Stock Price

EUR 22.50-2.80 (-11.07%)

Market Cap: $264.5M

Historical price data

Market Cap: $264.5MFounded: 1997Employees: 500-1000HQ: Les Ulis, France

Sector Ranking#92 in Diagnostics & Precision Medicine

Overview

Eurobio Scientific is a global specialty diagnostics company with a mission to improve patients' quality of life through innovative diagnostic solutions. The company has established a dual business model, generating over 30% of its revenue from proprietary products like prognostic genomic tests for cancer and transplant matching reagents, while also acting as a leading independent distributor for other IVD manufacturers. Its strategy focuses on leading breakthrough innovation in its core fields by developing and supporting a comprehensive portfolio of molecular diagnostics technologies. With a commercial footprint in over 90 countries and local affiliates in more than 10, Eurobio Scientific is an established, revenue-generating player in the diagnostics market.

OncologyTransplantationInfectious Diseases

Technology Platform

Integrated expertise across prognostic genomic testing, molecular diagnostics (PCR), immunoassays (ELISA), and specialized reagents for transplantation and life science research.

Funding History

1

IPOUndisclosedUndisclosedJun 15, 2005

Opportunities

The company is positioned to capitalize on the global growth in personalized medicine, particularly in oncology prognostics and transplant diagnostics.

Its hybrid model of proprietary products and distribution provides multiple revenue streams and opportunities for cross-selling.

Geographic expansion through its existing affiliate network offers a clear path for increasing market share.

Risk Factors

Key risks include regulatory hurdles for new tests, intense competition from larger diagnostics firms, dependence on reimbursement policies for proprietary assays, and potential disruption from rapid technological changes in molecular diagnostics.

The distribution business is also subject to the risk of losing key partner agreements.

Competitive Landscape

Eurobio Scientific competes with large IVD conglomerates (e.g., Roche, Thermo Fisher) in distribution and specific test segments, and with specialized genomic firms (e.g., Exact Sciences, Myriad) in oncology. Its focused expertise in transplantation diagnostics provides a defensible niche against players like CareDx and Immucor.